/KA

KA Stock - Kineta, Inc.

Q: What is the analyst price target for KA?

Analyst price target information is not currently available for KA.

Q: What is KA's market cap?

Market capitalization information is not currently available for KA.

Healthcare|Biotechnology|NASDAQ

$0.57-30.77%

$0.26 (-30.77%) • Sep 18

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.63

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for KA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.57

52W High$5.39

52W Low$0.33

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	$5.44M	$1.95M	$9.09M	$10.49M
Gross Profit	N/A	$5.43M	$1.22M	$8.42M	$10.49M
Gross Margin	N/A	99.8%	62.4%	92.6%	100.0%
Operating Income	$-13,532,000	$-15,723,000	$-41,531,000	$-11,093,000	$-3,115,000
Net Income	$-17,132,000	$-14,099,000	$-63,067,000	$-11,960,000	$-13,877,000
Net Margin	N/A	-259.1%	-3229.2%	-131.6%	-132.3%
EPS	$-1.42	$-1.28	$-12.80	$-8.14	$-41.26

Company Overview

Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.

Visit Website

Earnings History & Surprises

Beat Rate

73%

Last 15 quarters

Avg Surprise

+14.9%

EPS vs Estimate

Beats / Misses

11/4

Last 12 quarters

Latest EPS

$-0.13

Q2 2025

EPS Surprise History

Q3 23

+87.1%

$-0.08vs$-0.62

Q4 23

+16.4%

$-0.46vs$-0.55

Q1 24

+34.5%

$-0.19vs$-0.29

Q2 24

-323.8%

$-0.89vs$-0.21

Q3 24

+9.1%

$-0.20vs$-0.22

Q4 24

No data

Q1 25

No data

Q2 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2025	Aug 6, 2025	—	—	—	—
Q2 2025	May 13, 2025	—	$-0.13	—	—
Q1 2025	Mar 19, 2025	—	$-0.14	—	—
Q4 2024	Nov 1, 2024	—	$-0.46	—	—
Q3 2024	Aug 8, 2024	$-0.22	$-0.20	+9.1%	✓ BEAT
Q2 2024	May 15, 2024	$-0.21	$-0.89	-323.8%	✗ MISS
Q1 2024	Mar 21, 2024	$-0.29	$-0.19	+34.5%	✓ BEAT
Q4 2023	Nov 3, 2023	$-0.55	$-0.46	+16.4%	✓ BEAT
Q3 2023	Aug 11, 2023	$-0.62	$-0.08	+87.1%	✓ BEAT
Q2 2023	May 11, 2023	$-0.72	$-0.77	-6.9%	✗ MISS
Q1 2023	Mar 24, 2023	—	$7.00	—	—
Q4 2022	Nov 14, 2022	$-7.56	$-2.17	+71.3%	✓ BEAT
Q3 2022	Aug 4, 2022	$-6.93	$-3.15	+54.5%	✓ BEAT
Q2 2022	May 12, 2022	$-6.65	$-6.16	+7.4%	✓ BEAT
Q1 2022	Mar 24, 2022	$-7.37	$-7.00	+5.0%	✓ BEAT
Q4 2021	Nov 15, 2021	$-7.91	$-6.79	+14.2%	✓ BEAT
Q3 2021	Aug 12, 2021	$-5.88	$-7.21	-22.6%	✗ MISS
Q2 2021	May 17, 2021	$-5.81	$-5.95	-2.4%	✗ MISS
Q1 2021	Mar 31, 2021	$-19.60	$27.72	+241.4%	✓ BEAT
Q4 2020	Nov 16, 2020	$-25.20	$-15.40	+38.9%	✓ BEAT